CRISPR Fundamentals

CRSP
 Stock
  

USD 63.28  3.62  5.41%   

CRISPR Therapeutics AG fundamentals help investors to digest information that contributes to CRISPR Therapeutics' financial success or failures. It also enables traders to predict the movement of CRISPR Stock. The fundamental analysis module provides a way to measure CRISPR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CRISPR Therapeutics stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 28th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.

CRISPR Number of Shares Shorted Analysis

CRISPR Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
 2021 2022 (projected)
Interest Expense9.26 M9.99 M
Gross Profit914.96 M987.2 M
Shares Shorted 
 = 
Shorted by Public 
by Institutions 
More About Number of Shares Shorted | All Equity Analysis

Current CRISPR Therapeutics Number of Shares Shorted

    
  10.23 M  
Most of CRISPR Therapeutics' fundamental indicators, such as Number of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CRISPR Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Compare to competition

Based on the recorded statements, CRISPR Therapeutics AG has 10.23 M of outstending shares currently sold short by investors. This is 219.76% higher than that of the Healthcare sector and 100.69% higher than that of the Biotechnology industry. The number of shares shorted for all United States stocks is 117.41% lower than that of the firm.

CRISPR Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining CRISPR Therapeutics's current stock value. Our valuation model uses many indicators to compare CRISPR Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CRISPR Therapeutics competition to find correlations between indicators driving CRISPR Therapeutics's intrinsic value. More Info.
CRISPR Therapeutics AG is number one stock in price to sales category among related companies. It is number one stock in earnings per share category among related companies creating about  0.68  of Earnings Per Share per Price to Sales. The ratio of Price to Sales to Earnings Per Share for CRISPR Therapeutics AG is roughly  1.47 . As of 28th of June 2022, Earnings Before Interest Taxes and Depreciation Amortization EBITDA is likely to grow to about 428.9 M. Also, Earnings before Tax is likely to grow to about 409.5 M. Comparative valuation analysis is a catch-all model that can be used if you cannot value CRISPR Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for CRISPR Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CRISPR Therapeutics' earnings, one of the primary drivers of an investment's value.
CRISPR Therapeutics AG is the top company in total debt category among related companies. Total debt of Biotechnology industry is currently estimated at about 36.55 Billion. CRISPR Therapeutics maintains roughly 238.98 Million in total debt contributing less than 1% to stocks in Biotechnology industry.
Total debt  Valuation  Capitalization  Revenue  Workforce

CRISPR Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CRISPR Therapeutics from analyzing CRISPR Therapeutics' financial statements. These drivers represent accounts that assess CRISPR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CRISPR Therapeutics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets295.25 M433.88 M694.87 M1.34 B2.61 B2.81 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings Before Interest Taxes and Depreciation Amortization USD(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings before Tax(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Average Equity194.94 M341.25 M569.7 M1.2 B2.33 B2.51 B
Enterprise Value706.46 M992.24 M2.77 B9.81 B4.98 B4.53 B
Free Cash Flow(77.91 M)(99.01 M)49.99 M(256.72 M)457.27 M493.37 M
Invested Capital13.58 M1.17 M113.14 M609.49 M1.92 B2.07 B
Invested Capital Average13.29 M5.81 M74.92 M295.1 M1.48 B1.6 B
Market Capitalization963.13 M1.48 B3.36 B10.82 B5.8 B5.29 B
Tangible Asset Value271 M488.73 M1.07 B1.83 B2.75 B2.97 B
Working Capital233.87 M438.65 M930.44 M1.62 B2.3 B2.48 B

CRISPR Fundamentals

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue13.3 M13.7 M
Revenues915 M987.2 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Altman Z Score analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.